AZN not knowing while they co-authored the 2019 paper and getting CC'd on NDA filings is a stretch.
I find this Twitter thread by a sometimes co-author (Nephrologist Daniel Coyne) is a short and interesting read. The AstraZenica response should prove interesting. There is no reason for me to disbelieve Dr. Coyne's statement of non-knowledge of post-hoc modifications.
This dropped yesterday at 5:00 ET. I will thread details and my initial thoughts...https://t.co/5A2LuISCyK
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.